Skip to main content
. 2009 May 29;76(2):342–355. doi: 10.1124/mol.109.056523

Fig. 2.

Fig. 2.

Sorafenib and vorinostat toxicity is enhanced by GX15-070 in SW480 cells. A, HCT116 cells were, as indicated, infected with recombinant adenoviruses, and 24 h after infection, cells were treated with vehicle, sorafenib, vorinostat, or both drugs together. Forty-eight hours after exposure, cells were isolated and stained with Annexin V-propidium iodide, and cell viability was determined by flow cytometry (± S.E.M., n = 3). *, p < 0.05 less than corresponding value in CMV vector cells. Inset, expression of BCL-XL 24 h after infection. B, HCT116 cells were treated with vehicle or GX15-070 followed by, as indicated, vehicle, sorafenib, sodium valproate, or sorafenib + valproate. Twenty-four and 48 h after exposure, cells were isolated and viability determined via Annexin V-propidium iodide, and cell viability was determined by flow cytometry (± S.E.M., n = 3 independent studies). #, p < 0.05 greater than corresponding value in HCT116 cells (compare Fig. 1B). C, SW480 cells, 24 h after plating in triplicate, were treated with vehicle or GX15-070 followed by, as indicated, vehicle (DMSO), sorafenib, sodium valproate, or sorafenib + valproate. Twenty-four and 48 h after exposure, cells were isolated and viability determined via Annexin V-propidium iodide, and cell viability was determined by flow cytometry (± S.E.M., n = 3 independent studies). D, SW480 cells were transfected with siRNA molecules to knock down CD95. Twenty-four hours after transfection, cells were treated with vehicle or GX15-070 followed by, as indicated, vehicle, sorafenib, sodium valproate, or sorafenib + valproate. Twenty-four and 48 h after exposure, cells were isolated, and viability was determined via Annexin V-propidium iodide, and cell viability was determined by flow cytometry (± S.E.M., n = 2 independent studies). *, p < 0.05 less than corresponding value in siSCR transfected cells. E and F, OVCAR, SKOVIII, Rh30, and Rh41 cells were treated with vehicle or GX15-070 followed by, as indicated, vehicle, sorafenib, vorinostat, sodium valproate, sorafenib + valproate, or sorafenib + vorinostat. Forty-eight hours after exposure, cells were isolated and viability was determined via trypan blue exclusion assay (± S.E.M., n = 3 independent studies). #, p < 0.05 greater than sorafenib + vorinostat value. G and H, OVCAR and Rh41 cells were transfected with siRNA molecules to knock down CD95. Twenty-four hours after transfection, cells were treated with vehicle or GX15-070 followed by, as indicated, vehicle, sorafenib, sodium valproate, or sorafenib + valproate. Twenty-four and 48 h after exposure, cells were isolated and viability was determined via trypan blue exclusion assay (± S.E.M., n = 2 independent studies). *, p < 0.05 less than corresponding value in siSCR-transfected cells.